Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 205 results for lymphoma

  1. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    In development Reference number: GID-TA10774 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

    This guidance has been updated and replaced by NICE technology appraisal guidance 629.

    Withdrawn guidance

  4. Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1059.

    Withdrawn guidance

  5. The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma (TA37)

    This guidance has been updated and replaced by NICE technology appraisal guidance 137.

    Withdrawn guidance

  6. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued Reference number: GID-TA10961

    Technology appraisal guidance
    Discontinued

  7. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)

    Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    15 January 2025

    Sections for TA1030

  8. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued

  9. Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)

    This guidance has been updated and replaced by NICE technology appraisal guidance 604.

    Withdrawn guidance

  10. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    Discontinued Reference number: GID-TA11001

    Technology appraisal guidance
    Discontinued

  11. Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]

    In development Reference number: GID-TA11908 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Discontinued Reference number: GID-TA11486

    Technology appraisal guidance
    Discontinued

  13. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  14. Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

    This guideance has been updated and replaced by NICE technology appraisal guidance 422.

    Withdrawn guidance

  15. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA900